annual meeting program - American Society of Clinical Oncology

Monday, June 7, 2010
Brd. 7A Correlation of immune responses with survival in a randomized phase II
study investigating multipeptide vaccination with IMA901 plus or minus
low-dose cyclophosphamide in advanced renal cell carcinoma (RCC).
(Abstract #2587)
H. Singh, N. Hilf, R. Mendrzyk, D. Maurer, T. Weinschenk, A. Kirner, J. Frisch,
C. Reinhardt, A. Stenzl, S. Walter
Brd. 7B Improving patient selection for oncology phase I trials: Predictors of 90-day
mortality and overall survival. (Abstract #2588)
N. G. Chau, A. Florescu, K. K. Chan, L. Wang, E. X. Chen, A. M. Oza, L. L. Siu
Brd. 7C Phase IB study of eribulin mesylate in combination with carboplatin in
patients with advanced solid tumors. (Abstract #2589)
U. Swami, D. P. Petrylak, H. Raftopoulos, D. E. Shuster, G. Wang, V. Kumar,
G. Martinez, S. Goel, J. Aisner
Brd. 7D Phase I/II study of BIBW 2992 with or without daily temozolomide in the
treatment of patients with recurrent malignant glioma. (Abstract #2590)
D. A. Reardon, Y. Fu, H. C. Thurm, on behalf of the Phase I Study Group
Brd. 7E A phase I study of sirolimus (rapamycin) and bevacizumab in patients with
advanced malignancies. (Abstract #2591)
E. E. Cohen, M. Sharma, L. A. Janisch, W. M. Stadler, S. P. Kang, G. F. Fleming,
M. J. Ratain
Brd. 7F A phase II, single-arm clinical trial involving an alternative cancer treatment
psorinum therapy in patients with advanced non-small cell lung cancer
(NSCLC). (Abstract #2592)
A. Chatterjee, J. Biswas, A. K. Chatterjee, S. Bhattacharya, B. P. Mukhopadhyay,
A. Chakraborty, S. Das, R. S. Bhakta
Brd. 7G Capecitabine after anthracycline and taxane exposure in HER2-negative
metastatic breast cancer patients: Response, survival, and prognostic
factors. (Abstract #2593)
M. Gilabert, B. Esterni, F. Bertucci, P. Viens, A. Goncalves
Brd. 7H Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular
disrupting agent OXi4503 in patients with advanced solid tumors.
(Abstract #2594)
M. Zweifel, D. M. Patterson, A. R. Padhani, M. R. Middleton, P. Price,
M. R. Stratford, P. Ross, S. Halford, Z. Goldberg, G. J. Rustin
Brd. 8A Phase I trial of sequential azacitidine and valproic acid plus carboplatin in the
treatment of patients with advanced malignancies. (Abstract #2595)
E. Bustinza-Linares, G. S. Falchook, S. Fu, A. Naing, D. S. Hong, W. Hu,
S. L. Moulder, J. J. Wheler, A. Sood, R. Kurzrock
Brd. 8B Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after
multiple oral doses to advanced cancer patients. (Abstract #2596)
W. Tan, K. D. Wilner, Y. Bang, E. L. Kwak, R. G. Maki, D. R. Camidge,
B. J. Solomon, S. I. Ou, R. Salgia, J. W. Clark
Brd. 8C Hyperglycemia, hypertriglyceridemia, and hypercholesterolemia in a phase I
trial of the combination of an mTOR inhibitor and IGF-1 receptor inhibitor.
(Abstract #2597)
N. Busaidy, R. Kurzrock, P. LoRusso, A. D. Owens, H. X. Chen, L. Doyle, J. Zhang,
K. Lawhorn, C. Chandhasin, A. Naing
Brd. 8D Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and
bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast
cancer (MBC). (Abstract #2598)
M. Kozloff, G. W. Sledge, F. M. Benedetti, A. Starr, J. A. Wallace, M. J. Stuart,
D. Gruver, K. Miller
Brd. 8E A phase I study to determine the comparative bioavailability of two different
oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with
advanced solid tumors. (Abstract #2599)
L. R. Molife, M. D. Forster, M. Krebs, T. Pwint, M. R. Middleton, S. B. Kaye,
P. McCormack, H. Swaisland, J. Carmichael, M. Ranson
305
MONDAY